Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.